Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1199 results
October 2019
-
Media ReleaseNovartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in ankylosing spondylitisNew Cosentyx® (secukinumab) label to include 300 mg up-titration option is informed by results from the Phase III MEASURE 3 study[1] Approval provides clinicians with greater choice for their…
-
Key ReleaseNovartis verzeichnet ein weiteres starkes Quartal mit zweistelligem Umsatz-wachstum und höherer Kerngewinnmarge1; Umsatz- und Gewinnerwartung für 2019 angehoben; US-Einführung von BeovuDer Nettoumsatz der fortzuführenden Geschäftsbereiche2 steigt aufgrund folgender Beiträge um 13% (kWk1, +10% USD): Cosentyx erzielt einen Umsatz von USD 937 Millionen (+27% kWk)…
-
Key ReleaseNovartis, encore un fort trimestre: croissance à deux chiffres des ventes et expansion de la marge core1; hausse des prévisions de chiffre d’affaires et de résultat en 2019; Beovu lancé aux USAChiffre d’affaires net des activités poursuivies2 en hausse de 13% (tcc1, +10% USD) soutenu par: Cosentyx: USD 937 millions (+27% tcc), avec une forte demande dans toutes les indications et…
-
Key ReleaseNovartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in USContinuing operations2 net sales up 13% (cc1, +10% USD) driven by: Cosentyx sales of USD 937 million (+27% cc), with strong demand across indications and regionsEntresto USD 430 million (+61% cc…
-
Media ReleaseNovartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host diseaseREACH2 trial results confirm Jakavi significantly improves overall response rate (ORR) at 28 days vs. best available therapy in steroid-refractory acute graft-versus-host disease (GvHD)[1] GvHD…
-
Media ReleaseNovartis data show Cosentyx® treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitisNew two-year data compare the effects of Cosentyx (secukinumab) treatment in psoriatic arthritis patients with and without enthesitis, a manifestation described in 30-50% of patients [1] Results…
-
Media ReleaseNovartis real-world evidence confirms high efficacy, long-term response and favorable safety profile of Cosentyx® in clinical practiceData from five real-world evidence (RWE) and observational studies being conducted in North America, Latin America and Europe provide extensive cumulative insights for Cosentyx (secukinumab) clinical…
-
Media ReleaseNovartis data show more patients are completely symptom-free from chronic spontaneous urticaria with ligelizumab (QGE031) than Xolair® 300 mgResults from a Phase IIb dose-finding study show an average complete response rate of 42% for doses 240 mg and 72 mg ligelizumab at Week 12 compared with 26% for those taking 300 mg Xolair’s dose (…
-
Key ReleaseNovartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs afliberceptIn two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of…
-
Media ReleaseAveXis presents updated STRONG data at WMSOlder patients (≥ 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follow-up…
-
Key ReleaseNovartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrumPhase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)[1] Novartis plans FDA submission…
-
Media ReleaseNovartis and Microsoft announce collaboration to transform medicine with artificial intelligenceMultiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercializedNovartis to establish…
Pagination
- ‹ Previous page
- 1
- …
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- …
- 100
- › Next page